What does the evidence say about Curcumin Knee Pain Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Curcumin Knee Pain Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Results Compared to the placebo, VAS-101 was associated with greater improvements in the KOOS pain score (primary outcome measure) (β: 5.12; 95% CI: 0.47, 9.77; d = 0.62, p = 0.041), and mean daily pain ratings (F 3, 225 = 4.42; d = 0.55, p = 0.005). [Lopresti AL (2026); evidence level 2] - In the VAS-101 group, 39.3% of participants reported feeling either much or very much improved, compared with 13.3% in the placebo group ( p = 0.019). [Lopresti AL (2026); evidence level 2] - Conclusions Conservative dosing of a topically applied curcumin-containing gel (VAS-101), administered every two days for 28 days, is associated with moderate reductions in knee pain in adults with knee osteoarthritis. [Lopresti AL (2026); evidence level 2] - Background The oral delivery of curcumin has been shown in several studies to have beneficial pain-relieving effects for the treatment of knee osteoarthritis. [Lopresti AL (2026); evidence level 2] - 1 2 Arthritis constitutes a major global health burden and remains one of the leading causes of chronic pain, disability, and reduced quality of life worldwide. [Toumi Hechmi (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.